Compare Stocks

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNST Constellation Pharmaceuticals	$33.99	$33.89	$17.00 ▼ $39.30	$1.63B	2.59	940,325 shs	N/A
CNTTF CannTrust		$9.60	$4.35 ▼ $11.97	$1.01B	4.52	528,025 shs	1.43 million shs
DOVA Dova Pharmaceuticals	$28.04	$28.04	$5.62 ▼ $28.54	$807.55M	2.74	499,313 shs	35,036 shs
ZIOP ZIOPHARM Oncology		$1.08	$0.77 ▼ $5.95	$187.12M	1.71	2.01 million shs	2.13 million shs

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNST Constellation Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
CNTTF CannTrust	0.00%	0.00%	0.00%	0.00%	0.00%
DOVA Dova Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
ZIOP ZIOPHARM Oncology	0.00%	0.00%	0.00%	0.00%	0.00%

SHOCKING Crypto Leak… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CNST Constellation Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CNTTF CannTrust	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DOVA Dova Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZIOP ZIOPHARM Oncology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNST Constellation Pharmaceuticals	N/A	N/A	N/A	N/A
CNTTF CannTrust	N/A	N/A	N/A	N/A
DOVA Dova Pharmaceuticals	N/A	N/A	N/A	N/A
ZIOP ZIOPHARM Oncology	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNST Constellation Pharmaceuticals	N/A	N/A	N/A	N/A	$8.63 per share	N/A
CNTTF CannTrust	$15.96M	0.00	N/A	N/A	N/A	NaN
DOVA Dova Pharmaceuticals	$10.35M	78.02	N/A	N/A	$2.71 per share	10.35
ZIOP ZIOPHARM Oncology	N/A	N/A	N/A	N/A	$0.58 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNST Constellation Pharmaceuticals	-$126.36M	-$2.81	N/A	N/A	N/A	N/A	-33.12%	-29.92%	N/A
CNTTF CannTrust	N/A	$0.07	137.18	0.00	N/A	N/A	N/A	N/A	N/A
DOVA Dova Pharmaceuticals	-$72.28M	-$2.60	N/A	N/A	N/A	-544.09%	-101.60%	-67.21%	N/A
ZIOP ZIOPHARM Oncology	-$79.98M	-$0.43	N/A	N/A	N/A	N/A	-92.84%	-72.46%	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNST Constellation Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CNTTF CannTrust	N/A	N/A	N/A	N/A	N/A
DOVA Dova Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZIOP ZIOPHARM Oncology	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNST Constellation Pharmaceuticals	N/A	15.39	15.39
CNTTF CannTrust	N/A	N/A	N/A
DOVA Dova Pharmaceuticals	0.41	5.64	5.37
ZIOP ZIOPHARM Oncology	0.18	3.43	3.43

Ownership

Institutional Ownership

Company	Institutional Ownership
CNST Constellation Pharmaceuticals	N/A
CNTTF CannTrust	0.08%
DOVA Dova Pharmaceuticals	33.03%
ZIOP ZIOPHARM Oncology	51.03%

Insider Ownership

Company	Insider Ownership
CNST Constellation Pharmaceuticals	43.70%
CNTTF CannTrust	N/A
DOVA Dova Pharmaceuticals	60.30%
ZIOP ZIOPHARM Oncology	5.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CNST Constellation Pharmaceuticals	154	47.92 million	N/A	Not Optionable
CNTTF CannTrust	N/A	105.61 million	N/A	Not Optionable
DOVA Dova Pharmaceuticals	115	28.80 million	N/A	Optionable
ZIOP ZIOPHARM Oncology	105	216.15 million	204.91 million	Optionable

CNST, ZIOP, DOVA, and CNTTF Headlines

Source	Headline
	Childhood Cancers curetoday.com - February 17 at 5:57 PM
	Alx Oncology Holdings (ALXO) investing.com - February 10 at 8:15 PM
	Pediatric Hematology-Oncology Fellowship bcm.edu - February 5 at 8:39 AM
	Alaunos Therapeutics: Other Events, Financial Statements And Exhibits cbonds.com - January 31 at 9:44 AM
	CG Oncology Inc reuters.com - January 31 at 4:43 AM
	Oncology Nurses' Narratives About Ethical Dilemmas and Prognosis-Related Communication in Advanced Cancer Patients medscape.com - December 21 at 3:43 PM
	Immuno-Oncology ajmc.com - December 19 at 3:21 PM
	Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today? markets.businessinsider.com - December 18 at 8:18 AM
	Exploring Patient-Centered Handoffs in Surgical Oncology medscape.com - December 10 at 7:36 PM
	Association of Community Cancer Centers ajmc.com - October 14 at 2:50 PM
	Oncology News and Research news-medical.net - September 19 at 5:53 PM
	WBSPH 2024 - Oncology newsweek.com - September 15 at 8:49 PM
	Kris on Oncology medscape.com - September 6 at 11:16 PM
	Gauging Ziopharm's Chances for Positive Sarcoma Drug Trial Results thestreet.com - August 29 at 6:23 AM
	Oncology Cases & Quizzes medscape.com - August 14 at 6:15 PM
	Ziopharm’s palifosfamide fails in first-line STS… investing.com - June 21 at 12:05 AM
	Weber on Oncology medscape.com - June 19 at 2:11 PM
	A Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in Melanoma ascopubs.org - June 17 at 8:43 AM
	ALX Oncology Holdings Inc Ordinary Shares morningstar.com - June 15 at 6:54 PM
	Division of Pediatric Hematology and Oncology slu.edu - June 13 at 3:50 PM
	Division of Hematology and Medical Oncology slu.edu - June 13 at 3:50 PM
	Intratumoral Cancer Therapies Global Market Report 2023 finance.yahoo.com - June 9 at 1:32 PM
	Natural Killer Cell Therapy Market 2023-2029 New Research Report by Industryreport.co marketwatch.com - May 11 at 9:52 PM
	VC Identifies 3 Startups That Will Shake Up the Future of Cancer Care medcitynews.com - May 10 at 1:58 AM

Company Descriptions

Constellation Pharmaceuticals

NASDAQ:CNST

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

CannTrust

OTCMKTS:CNTTF

CannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.

Dova Pharmaceuticals

NASDAQ:DOVA

Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. It also develops DOPTELET for the treatment of chronic immune thrombocytopenia and chemotherapy-induced thrombocytopenia. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina.

ZIOPHARM Oncology

NASDAQ:ZIOP

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial